This document was published in 2025.
We made 73 statements for the delivery of an IBD colorectal surveillance service, including outcome standards for service and endoscopist audit, and the importance of shared decision-making with patients. Core areas include: risk of colorectal cancer, IBDrelated post-colonoscopy colorectal cancer; service organisation and supporting patient concordance; starting and stopping surveillance, who should or should not receive surveillance; risk stratification, including web-based multivariate risk calculation of surveillance intervals; colonoscopic modalities, bowel preparation, biomarkers and artificial intelligence aided detection; chemoprevention; the role of non-conventional dysplasia, serrated lesions and non-targeted biopsies; management of dysplasia, both endoscopic and surgical, and the structure and role of the multidisciplinary team in IBD dysplasia management; training in IBD colonoscopic surveillance, sustainability (green endoscopy), costeffectiveness and patient experience. Sixteen research priorities are suggested
Abstract
Patients with inflammatory bowel disease (IBD) remain at increased risk for colorectal cancer and death from colorectal cancer compared with the general population despite improvements in inflammation control with advanced therapies, colonoscopic surveillance and reductions in environmental risk factors. This guideline update from 2010 for colorectal surveillance of patients over 16 years with colonic inflammatory bowel disease was developed by stakeholders representing UK physicians, endoscopists, surgeons, specialist nurses and patients with GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodological support. An a priori protocol was published describing the approach to three levels of statement: GRADE recommendations, good practice statements or expert opinion statements. A systematic review of 7599 publications, with appraisal and GRADE analysis of trials and network meta-analysis, where appropriate, was performed. Risk thresholding guided GRADE judgements.We made 73 statements for the delivery of an IBD colorectal surveillance service, including outcome standards for service and endoscopist audit, and the importance of shared decision-making with patients. Core areas include: risk of colorectal cancer, IBDrelated post-colonoscopy colorectal cancer; service organisation and supporting patient concordance; starting and stopping surveillance, who should or should not receive surveillance; risk stratification, including web-based multivariate risk calculation of surveillance intervals; colonoscopic modalities, bowel preparation, biomarkers and artificial intelligence aided detection; chemoprevention; the role of non-conventional dysplasia, serrated lesions and non-targeted biopsies; management of dysplasia, both endoscopic and surgical, and the structure and role of the multidisciplinary team in IBD dysplasia management; training in IBD colonoscopic surveillance, sustainability (green endoscopy), costeffectiveness and patient experience. Sixteen research priorities are suggested
Read the guideline launch statement here.
Read More
Clinical Resources
Position Statements
British Society of Gastroenterology and Association of Coloproctology of Great Britain and Ireland position on tranexamic acid in upper and lower gastrointestinal bleeding
clinical-resource/Tranexamic-acid-in-upper-lower-GI-bleeding
Following a concern raised to NHS England’s National Patient Safety Team regarding tranexamic acid use in gastrointestinal bleeding, and in light of the 2020 publication of the HALT-IT trial results,
Guidance
BSG Nurses Association
Endoscopy
BSG, ACPGBI and AUGIS guidance on the scope of professional practice for clinical endoscopists
clinical-resource/Guidance-on-practice-for-clinical-endoscopists
This document focuses on the scope of professional practice for clinical endoscopists (previously known as non- medical endoscopists/nurse endoscopists).